Published in J Transl Med on December 07, 2011
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther (2014) 1.12
Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle (2013) 1.08
Altered fate of tendon-derived stem cells isolated from a failed tendon-healing animal model of tendinopathy. Stem Cells Dev (2012) 0.94
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. Sci Rep (2014) 0.93
Increased invasion and tumorigenicity capacity of CD44+/CD24- breast cancer MCF7 cells in vitro and in nude mice. Cancer Cell Int (2013) 0.91
Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy. PLoS One (2013) 0.90
The implications of cancer stem cells for cancer therapy. Int J Mol Sci (2012) 0.87
Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med (2013) 0.85
IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol (2014) 0.84
Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment. Onco Targets Ther (2012) 0.84
Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer. PLoS One (2013) 0.83
Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer (2012) 0.83
Biological and clinical significance of cancer stem cell plasticity. Clin Transl Med (2014) 0.82
CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. Oncotarget (2015) 0.82
Enrichment and characterization of cancer stem‑like cells from a cervical cancer cell line. Mol Med Rep (2014) 0.82
Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties. Cytotechnology (2012) 0.81
A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells. Stem Cell Res Ther (2016) 0.81
CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2. Br J Cancer (2014) 0.81
Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer. J Steroid Biochem Mol Biol (2014) 0.81
Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget (2016) 0.80
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer (2015) 0.79
Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression. Onco Targets Ther (2015) 0.78
Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition. Int J Biol Sci (2015) 0.78
Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations. Onco Targets Ther (2015) 0.78
Mammosphere formation assay from human breast cancer tissues and cell lines. J Vis Exp (2015) 0.78
Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells. Oxid Med Cell Longev (2015) 0.78
Activation of RARα induces autophagy in SKBR3 breast cancer cells and depletion of key autophagy genes enhances ATRA toxicity. Cell Death Dis (2015) 0.77
A new prospect in cancer therapy: targeting cancer stem cells to eradicate cancer. Chin J Cancer (2012) 0.75
Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results. Onco Targets Ther (2016) 0.75
Diagnostic value of Wilms tumor 1 and CD44 in Langerhans cell sarcoma: case series of 4 patients. Medicine (Baltimore) (2015) 0.75
All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy. BMC Complement Altern Med (2016) 0.75
Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. J Steroid Biochem Mol Biol (2016) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer (2004) 8.06
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A (2007) 4.97
Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer (2003) 4.86
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene (2008) 4.53
Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst (2006) 4.47
Requirement for beta-catenin in anterior-posterior axis formation in mice. J Cell Biol (2000) 4.36
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2010) 4.22
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood (2007) 2.79
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia (2001) 2.67
Cell surface-associated mucins in signal transduction. Trends Cell Biol (2006) 2.58
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development (2004) 2.45
Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem (1997) 2.32
Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell (2005) 2.23
MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene (2010) 1.99
Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets (2009) 1.91
Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One (2008) 1.90
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat (2009) 1.80
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer (2004) 1.79
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A (2008) 1.76
Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget (2010) 1.71
MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog (2009) 1.69
DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res (2009) 1.67
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol (2008) 1.58
Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle (2009) 1.56
Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis. Oncogene (2010) 1.45
MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene (2006) 1.38
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol (2003) 1.36
Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord (2005) 1.30
MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res (2006) 1.27
Expression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. Int J Cancer (2000) 1.23
Mucin and Toll-like receptors in host defense against intestinal parasites. Trends Parasitol (2003) 1.20
Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res (2010) 1.19
The patched/hedgehog/smoothened signalling pathway in human breast cancer: no evidence for H133Y SHH, PTCH and SMO mutations. Eur J Cancer (1999) 1.18
Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology (2006) 1.17
Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol (2009) 1.13
Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat (2010) 1.11
Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia (2009) 1.10
Heat shock proteins in breast cancer progression--a suitable case for treatment? Int J Hyperthermia (2010) 1.06
Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene (2004) 1.05
Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Onco Targets Ther (2011) 1.00
Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics (2011) 0.97
Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice. Cancer Sci (2010) 0.97
Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther (2010) 0.95
All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release (2010) 0.92
Fatty acid synthesis is a therapeutic target in human liposarcoma. Int J Oncol (2010) 0.91
Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids (2009) 0.89
Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. Anticancer Drugs (2010) 0.86
Acetaminophen-induced differentiation of human breast cancer stem cells and inhibition of tumor xenograft growth in mice. Biochem Pharmacol (2011) 0.82
Silencing HSF1 by short hairpin RNA decreases cell proliferation and enhances sensitivity to hyperthermia in human melanoma cell lines. J Dermatol Sci (2010) 0.81
Role of Lef1 in sustaining self-renewal in mouse embryonic stem cells. J Genet Genomics (2010) 0.80
Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen. Future Oncol (2011) 0.78
A meta-analysis of the antecedents and consequences of pay level satisfaction. J Appl Psychol (2006) 0.75